YHYao Hu

Yao Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yao Hu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Yu

    Department of Infectious Diseases, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, China

    3 shared publications
  • Lijing Ye

    Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China

    2 shared publications
  • Shuzhen Han

    Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China

    2 shared publications
  • Xia Wu

    Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China

    2 shared publications
  • Xiaohong Wang

    Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China

    2 shared publications
  • Yingzi Ye

    Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China; Key Development of Program of Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China

    2 shared publications

Latest Publications

  • Open Access

    Liver histology of treatment-naïve children with chronic hepatitis B virus infection in Shanghai China

    by Yao Hu, Xia Wu, Yingzi Ye, Lijing Ye, Shuzhen Han, Xiaohong Wang, Hui Yu


  • Open Access

    Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV

    by Zhong Fang, Yi Zhang, Zhaoqin Zhu, Cong Wang, Yao Hu, Xiuhua Peng, Dandan Zhang, Jun Zhao, Bisheng Shi, Zhongliang Shen, et al.

    Hepatitis B virus exposure in children usually develops into chronic hepatitis B (CHB). Although hepatitis B surface antigen (HBsAg)–specific CD8+ T cells contribute to resolve HBV infection, they are preferentially undetected in CHB patients. Moreover, the mechanism for this rarely detected HBsAg-specific CD8+ T cells remains unexplored. We herein found that the frequency of HBsAg-specific CD8+ T cells was inversely correlated with expansion of monocytic myeloid-derived suppressor cells (mMDSCs) in young rather than in adult CHB patients, and CCR9 was upregulated by HBsAg on mMDSCs via activation of ERK1/2 and IL-6. Sequentially, the interaction between CCL25 and CCR9 mediated thymic homing of mMDSCs, which caused the cross-presentation, transferring of peripheral HBsAg into the thymic medulla, and then promoted death of HBsAg-specific CD8+ thymocytes. In mice, adoptive transfer of mMDSCs selectively obliterated HBsAg-specific CD8+ T cells and facilitated persistence of HBV in a CCR9-dependent manner. Taken together, our results uncovered a novel mechanism for establishing specific CD8+ tolerance to HBsAg in chronic HBV infection.


  • Open Access

    Histology and Clinical Characteristics of Asymptomatic Treatment-naïve Children with Chronic Hepatitis B in Shanghai China

    by Yao Hu, Xia Wu, Yingzi Ye, Lijing Ye, Shuzhen Han, Qirong Zhu, Xiaohong Wang, Hui Yu

    BACKGROUND & AIMS: Chronic hepatitis B (CHB) virus infection is a major cause of morbidity and mortality. We aim to investigate the association between hepatic histology and clinical characteristics in asymptomatic treatment-naïve children chronically infected with hepatitis B virus (HBV) in Shanghai China. METHODS: Liver biopsies of 278 asymptomatic treatment-naïve children with chronic hepatitis B virus infection were scored for inflammation and fibrosis, and correlated with clinical and laboratory data. RESULTS: The clinical, virologic and pathologic features of chronic HBV infection were studied in 278 treatment-naïve children from Shanghai, China, of who were all asymptomatic. And 177 (63.7%) of the children were male. Sera from mothers of 277 of these children were HBsAg positive. Up to 87.4% of subjects were hepatitis B e antigen-positive at the time of the biopsy. The median age at biopsy was 5.1 years (interquartile range 2.8-8.4 years). HBV DNA levels were generally high (mean 7.4 log10 IU/mL), as was serum alanine aminotransferase (median 105 U/L). Using the Ishak-modified histology activity index scoring system, no inflammation was seen in 2.9% cases, mild inflammation was in 22.3%, moderate in 73.4%, and severe in 1.4%. No fibrosis was seen in 11.5%, mild fibrosis in 32.7%, moderate fibrosis in 47.5%, and cirrhosis in 8.3%. When serum ALT level was < 80 (2×ULN) and > 80 U/L, the degree of inflammation (PP3 years (PCONCLUSION: Significantly wide range of inflammation and fibrosis is seen in asymptomatic treatment-naïve children with chronic hepatitis B in Shanghai China. Serum ALT >80 U/L may be a strong indicator of the degree of hepatic inflammation and severity of fibrosis. Moderate fibrosis and cirrhosis has already appeared in aged <3 years children.

  • Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China

    by Yao Hu, Ying-Zi Ye, Li-Jing Ye, Xiao-Hong Wang, Hui Yu

    Interferon alpha (IFN-α) is a preferred therapy for antiviral treatment of children with chronic hepatitis B (CHB) aged > 1 year currently. Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years. But the exact efficacy and safety of IFN-α and Peg-IFN α-2a for treating CHB are not sufficient.